Emerging Biomarkers for the Detection of Cardiovascular Diseases

Overview

Journal Egypt Heart J

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2022 Oct 20

PMID 36264449

Authors

Sreenu Thupakula

Shiva Shankar Reddy Nimmala

Haritha Ravula

Sudhakar Chekuri

Raju Padiya

Affiliations

Soon will be listed here.

Abstract

Background: The prevalence of cardiovascular disease (CVD) has been continuously increasing, and this trend is projected to continue. CVD is rapidly becoming a significant public health issue. Every year there is a spike in hospital cases of CVD, a critical health concern in lower- and middle-income countries. Based on identification of novel biomarkers, it would be necessary to study and evaluate the diagnostic requirements or CVD to expedite early detection.

Main Body: The literature review was written using a wide range of sources, such as well-known medical journals, electronic databases, manuscripts, texts, and other writings from the university library. After that, we analysed the specific markers of CVD and compiled a systematic review. A growing body of clinical research aims to identify people who are at risk for cardiovascular disease by looking for biomolecules. A small number of biomarkers have been shown to be useful and reliable in medicine. Biomarkers can be used for a variety of clinical applications, such as predicting heart disease risk, diagnosing disease, or predicting outcomes. As a result of the ability for a single molecule to act as a biomarker, its usefulness in medicine is expected to increase significantly.

Conclusions: Based on assessing the current trends in the application of CVD markers, we discussed and described the requirements for the application of CVD biomarkers in coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other cardiovascular illnesses. Furthermore, the current review focuses on biomarkers for CVD and the procedures that should be considered to establish the comprehensive nature of the expression of biomarkers for cardiovascular illness.

Citing Articles

Development and optimisation of the biosensor for aspartate aminotransferase blood level determination.

Mruga D, Dzyadevych S, Soldatkin O Anal Bioanal Chem. 2024; 417(4):721-731.

PMID: 39666000 DOI: 10.1007/s00216-024-05682-2.

Lp(a) and high-sensitivity C-reactive protein are predictive biomarkers for coronary heart disease in Chinese patients with type 2 diabetes mellitus.

Meng Q, Ma H, Tian N, Wang Z, Cai L, Zhang Y Heliyon. 2024; 10(21):e40074.

PMID: 39553691 PMC: 11565462. DOI: 10.1016/j.heliyon.2024.e40074.

A Systematic Review and Meta-Analysis Assessing the Accuracy of Blood Biomarkers for the Diagnosis of Ischemic Stroke in Adult and Elderly Populations.

Ruksakulpiwat S, Zhou W, Phianhasin L, Benjasirisan C, Su T, Aldossary H eNeuro. 2024; 11(11).

PMID: 39528275 PMC: 11575121. DOI: 10.1523/ENEURO.0302-24.2024.

A Plasmonic Nanoledge Array Sensor for Selective Detection of Cardiovascular Disease Biomarkers in Human Whole Blood.

Tukur F, Mabe T, Liu M, Tukur P, Wei J ACS Appl Nano Mater. 2024; 7(17):20024-20033.

PMID: 39296866 PMC: 11406491. DOI: 10.1021/acsanm.4c02524.

miR-6089 may prevent the inflammatory events leading to cardiovascular disorders in RA patients.

Shamsi A, Roghani S, Shamsi M, Jalili C, Taghadosi M, Soufivand P Heliyon. 2024; 10(17):e36763.

PMID: 39281435 PMC: 11395719. DOI: 10.1016/j.heliyon.2024.e36763.

References

Johnson B, Kip K, Marroquin O, Ridker P, Kelsey S, Shaw L . Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004; 109(6):726-32. DOI: 10.1161/01.CIR.0000115516.54550.B1. View

Rabitzsch G, Mair J, LECHLEITNER P, Noll F, Hofmann V, Krause E . Isoenzyme BB of glycogen phosphorylase b and myocardial infarction. Lancet. 1993; 341(8851):1032-3. DOI: 10.1016/0140-6736(93)91129-a. View

Cheng J, Zhou T, Liu C, Shapiro J, BRAUER M, Kiefer M . Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263(5154):1759-62. DOI: 10.1126/science.7510905. View

Alkharfy K, Al-Daghri N, Vanhoutte P, Krishnaswamy S, Xu A . Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PLoS One. 2012; 7(10):e48612. PMC: 3485358. DOI: 10.1371/journal.pone.0048612. View

Weinberg E, Shimpo M, Hurwitz S, Tominaga S, Rouleau J, Lee R . Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003; 107(5):721-6. DOI: 10.1161/01.cir.0000047274.66749.fe. View

Migocka-Patrzalek M, Elias M . Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease. Cells. 2021; 10(4). PMC: 8070155. DOI: 10.3390/cells10040883. View

Deng H, Li J, Shah A, Lin G, Chen H, Ouyang W . Commonly expressed key transcriptomic profiles of sepsis in the human circulation and brain via integrated analysis. Int Immunopharmacol. 2022; 104:108518. DOI: 10.1016/j.intimp.2022.108518. View

Dowling P, Gargan S, Zweyer M, Sabir H, Swandulla D, Ohlendieck K . Proteomic profiling of carbonic anhydrase CA3 in skeletal muscle. Expert Rev Proteomics. 2021; 18(12):1073-1086. DOI: 10.1080/14789450.2021.2017776. View

Lowe G . Fibrinogen assays for cardiovascular risk assessment. Clin Chem. 2010; 56(5):693-5. DOI: 10.1373/clinchem.2010.145342. View

10.

Lopes D, Falcao L . Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis. Rev Port Cardiol. 2017; 36(6):465-472. DOI: 10.1016/j.repc.2016.11.009. View

11.

Loria V, Dato I, Graziani F, Biasucci L . Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm. 2008; 2008:135625. PMC: 2276594. DOI: 10.1155/2008/135625. View

12.

Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T . Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome--comparison with other biomarkers. J Cardiol. 2010; 56(2):159-65. DOI: 10.1016/j.jjcc.2010.05.002. View

13.

van Oers J, Kluiters Y, Bons J, de Jongh M, Pouwels S, Ramnarain D . Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: A prospective cohort study. J Crit Care. 2021; 66:173-180. PMC: 8289696. DOI: 10.1016/j.jcrc.2021.07.017. View

14.

Tourdot B, Ahmed I, Holinstat M . The emerging role of oxylipins in thrombosis and diabetes. Front Pharmacol. 2014; 4:176. PMC: 3882718. DOI: 10.3389/fphar.2013.00176. View

15.

Fenech G, Rajzbaum G, Mazighi M, Blacher J . Serum uric acid and cardiovascular risk: state of the art and perspectives. Joint Bone Spine. 2014; 81(5):392-7. DOI: 10.1016/j.jbspin.2014.01.008. View

16.

Kim A, Ro H, Kim H, Chang J, Lee H, Chung W . Soluble ST2 and Galectin-3 as Predictors of Chronic Kidney Disease Progression and Outcomes. Am J Nephrol. 2021; 52(2):119-130. DOI: 10.1159/000513663. View

17.

Hulsmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T . Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol. 1998; 32(6):1695-700. DOI: 10.1016/s0735-1097(98)00437-9. View

18.

. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 1979; 59(3):607-9. DOI: 10.1161/01.cir.59.3.607. View

19.

Klebanoff S . Myeloperoxidase: friend and foe. J Leukoc Biol. 2005; 77(5):598-625. DOI: 10.1189/jlb.1204697. View

20.

Fabbrini E, Serafini M, Colic Baric I, Hazen S, Klein S . Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2013; 63(3):976-81. PMC: 3931399. DOI: 10.2337/db13-1396. View